By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Purdue
Pharmaceutical Products L.P. et al. v. TWi Pharmaceuticals, Inc.
1:13-cv-05999;
filed August 22, 2013 in the Northern District of Illinios

• Plainiffs: 
Purdue Pharmaceutical Products L.P.; Purdue Pharma L.P.; Transcept
Pharmaceuticals, Inc.
• Defendant: 
TWi Pharmaceuticals, Inc.

Purdue
Pharmaceutical Products L.P. et al. v. TWI Pharmaceuticals, Inc.
2:13-cv-05003;
filed August 20, 2013 in the District Court of New Jersey

• Plaintiffs: 
Purdue Pharmaceutical Products L.P.; Purdue Pharma L.P.; Transcept
Pharmaceuticals, Inc.
• Defendant: 
Twi Pharmaceuticals, Inc.

The
complaints in these cases are substantially identical.  Infringement of U.S. Patent Nos. 8,242,131 ("Methods
of Treating Middle-of-the-Night Insomnia," issued August 14, 2012) and
8,252,809 ("Compositions for Treating Insomnia," issued August 28,
2012) following a Paragraph IV certification as part of TWI's filing of an ANDA
to manufacture a generic version of Purdue's Intermezzo® (sublingual zolpidem
tartrate, used to treat insomnia when middle-of-the-night awakening is followed
by difficulty returning to sleep).  View
the New Jersey complaint here.

Life
Technologies Corp. et al. v. Rea et al.
1:13-cv-01046;
filed August 21, 2013 in the Eastern District of Virginia

• Plaintiffs: 
Life Technologies Corp.; Life Technologies (Israel) Ltd.; Applied
Biosystems, LLC; Molecular Probes, Inc.
• Defendants: 
Teresa Stanek Rea; Office of the General Counsel

Review and
correction of the patent term adjustment calculation made by the U.S. Patent
and Trademark Office for a series of 36 patents on the basis of improper
termination of B-delay at the filing of a Request for Continued
Examination.   View the complaint here.

Reckitt
Benckiser Pharmaceuticals Inc. et al. v. Par Pharmaceutical Inc. et al.
1:13-cv-01461;
filed August 20, 2013 in the District Court of Delaware

• Plaintiffs: 
Reckitt Benckiser Pharmaceuticals Inc.; RB Pharmaceuticals Ltd.; MonoSol Rx
LLC
• Defendants: 
Par Pharmaceutical Inc.; IntelGenX Technologies Corp.; LTS Lohmann Therapy
Systems Corp.

Infringement
of U.S. Patent Nos. 8,475,832 ("Sublingual and Buccal Film Compositions,"
issued July 2, 2013) and 8,017,150 ("Polyethylene Oxide-Based Films and
Drug Delivery Systems Made Therefrom," issued on September 13, 2011) following
a Paragraph IV certification as part of Par's filing of an ANDA to manufacture
a generic version of Reckitt Benckiser's Suboxone® (buprenorphine hydrochloride
and naloxone hydrochloride sublingual film, used for the maintenance treatment
of opioid dependence).  View the
complaint here.

Teva Branded
Pharmaceutical Products R&D Inc. et al. v. Perrigo Pharmaceuticals Co. et
al.
1:13-cv-01441;
filed August 16, 2013 in the District Court of Delaware

• Plaintiffs: 
Teva Branded Pharmaceutical Products R&D Inc.; Teva Respiratory LLC; Norton
(Waterford) Ltd.; Norton Healthcare Ltd.
• Defendants: 
Perrigo Pharmaceuticals Co.; Perrigo Co.; Catalent Pharma Solutions LLC

Infringement
of U.S. Patent Nos. 7,566,445 ("Medicinal Aerosols and Methods of Delivery
Thereof," issued July 28, 2009), 7,105,152 ("Suspension Aerosol
Formulations," issued September 12, 2006), 6,446,627 ("Inhaler Dose
Counter," issued September 10, 2002), and 8,132,712 ("Metered-Dose Inhaler,"
issued March 13, 2012) following a Paragraph IV certification as part of
Perrigo's filing of an ANDA to manufacture a generic version of Teva's ProAir®
HFA Inhalation Aerosol (albuterol sulfate, used for the treatment or prevention
of bronchospasm with reversible obstructive airway disease in patients 4 years
of age and older and for the prevention of exercise-induced bronchospasm in
patients 4 years of age and older).  View
the complaint here.